ANSWER: B

Rationale:

The correct answer is B. Statins — including atorvastatin — are competitive inhibitors of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, which is the committed and rate-limiting step in the hepatic cholesterol biosynthesis pathway. By blocking this step, atorvastatin reduces intracellular cholesterol synthesis in hepatocytes. The resulting intracellular cholesterol deficit activates sterol regulatory element-binding protein 2 (SREBP-2), a transcription factor that upregulates expression of LDL receptors on the hepatocyte surface. The increased density of LDL receptors enhances receptor-mediated endocytosis of circulating LDL particles, lowering plasma LDL-C. This two-step mechanism — enzyme inhibition followed by compensatory receptor upregulation — is the defining pharmacological feature of the statin class and explains why statins are the most potent oral LDL-lowering agents available. The magnitude of LDL-C reduction is primarily determined by the degree of receptor upregulation rather than by the absolute reduction in hepatic cholesterol synthesis.

• Option A: Option A is incorrect; activation of PPARα is the mechanism of fibrates, not statins — fibrates lower triglycerides and raise HDL-C through LPL upregulation and are not the primary mechanism by which any statin lowers LDL-C.
• Option C: Option C is incorrect; blocking the NPC1L1 intestinal cholesterol transporter is the mechanism of ezetimibe, a structurally and mechanistically distinct drug that acts in the gut rather than in the liver.
• Option D: Option D is incorrect; inhibition of microsomal triglyceride transfer protein (MTP) is the mechanism of lomitapide, an orphan drug used in homozygous familial hypercholesterolemia — it is not a statin mechanism.
• Option E: Option E is incorrect; while statins do indirectly increase LDL receptor expression through SREBP-2 activation and while PCSK9 inhibition is a pharmacological strategy that also increases LDL receptor density, the primary mechanism of statins is HMG-CoA reductase inhibition, not PCSK9 inhibition — PCSK9 inhibitors are a separate drug class (monoclonal antibodies) with a distinct mechanism.

ANSWER: D

Rationale:

The correct answer is D. Statin-associated muscle symptoms (SAMS) represent a spectrum ranging from myalgia (muscle pain without CK elevation) through myositis (muscle symptoms with CK elevation) to the rare but serious rhabdomyolysis (CK >10× ULN with myoglobinuria and risk of renal failure). A CK elevation of 3–10× the upper limit of normal with concomitant muscle symptoms — as in this patient — falls in the middle of this spectrum and is managed by temporarily holding the statin, rechecking CK and symptoms in 2–4 weeks, and reassessing. If CK normalizes and symptoms resolve with drug holiday, the clinician can consider reintroduction (often at the same dose or a lower dose of the same agent, or switched to a more hydrophilic statin such as rosuvastatin or pravastatin) with careful follow-up. This approach confirms causality — the temporal relationship between drug holiday and symptom resolution is the strongest evidence that the statin was responsible — while preserving the option of statin therapy, which this patient needs for his elevated 10-year ASCVD risk. Permanent discontinuation without rechallenge is premature at this CK level and symptom severity.

• Option A: Option A is incorrect; immediate permanent discontinuation is not warranted for CK 3–10× ULN — this threshold triggers a hold-and-reassess strategy, not permanent drug abandonment; the threshold for urgent permanent discontinuation is CK >10× ULN or evidence of myoglobinuria or renal impairment.
• Option B: Option B is incorrect; a CK of nearly 3× ULN in a symptomatic patient is not within normal physiological variation and should not be dismissed — the combination of symptoms plus objective CK elevation requires active management, not watchful neglect at a 12-month interval.
• Option C: Option C is incorrect; while switching to a more hydrophilic statin is a reasonable strategy after the hold-and-reassess period confirms statin causality, immediately switching to maximum-dose rosuvastatin without a washout and without confirming symptom resolution is not the appropriate first step — and high-intensity rosuvastatin in a patient with active myopathy symptoms is not conservative management.
• Option E: Option E is incorrect; coenzyme Q10 supplementation has been studied in statin-associated myopathy but has not been shown in randomized controlled trials to reliably prevent or reverse SAMS — the evidence does not support it as a substitute for dose modification or drug holiday, and the claim that SAMS is caused exclusively by CoQ10 depletion oversimplifies a multifactorial mechanism.

ANSWER: A

Rationale:

The correct answer is A. Ezetimibe's mechanism of action is selective inhibition of NPC1L1 (Niemann-Pick C1-like 1), a sterol transporter expressed on the luminal surface of duodenal and jejunal enterocytes. NPC1L1 mediates the uptake of both dietary cholesterol (exogenous) and biliary cholesterol (which is secreted into the bile and recirculated through the intestine) from the gut lumen into enterocytes, from which it is packaged into chylomicrons and delivered to the liver via the portal circulation. By blocking NPC1L1, ezetimibe reduces cholesterol delivery to the liver, which reduces intrahepatic cholesterol content and triggers compensatory SREBP-2-mediated upregulation of hepatic LDL receptors — the same downstream consequence produced by statins through a different upstream mechanism. As monotherapy, ezetimibe reduces LDL-C by approximately 15–20%; in combination with a statin, it produces additive LDL-C lowering because the two drugs target independent steps in cholesterol homeostasis (hepatic synthesis versus intestinal absorption).

• Option B: Option B is incorrect; blocking bile acid reabsorption in the terminal ileum is the mechanism of bile acid sequestrants (cholestyramine, colestipol, colesevelam) — a drug class that predates ezetimibe and acts via a completely different molecular target; ezetimibe does not bind bile acids.
• Option C: Option C is incorrect; ezetimibe does not inhibit HMG-CoA reductase in any tissue — its target is the NPC1L1 cholesterol transporter, not the mevalonate pathway enzyme; the claim of intestinal-selective HMG-CoA reductase inhibition does not correspond to any approved lipid-lowering drug mechanism.
• Option D: Option D is incorrect; LXR activation and ABCG5/ABCG8 upregulation describe reverse cholesterol transport and sterol efflux biology — while these are relevant to cholesterol homeostasis, they are not the mechanism of ezetimibe; LXR agonists are investigational compounds not in clinical use.
• Option E: Option E is incorrect; inhibition of pancreatic cholesterol esterase is not the mechanism of ezetimibe, and while esterification status does affect the form in which cholesterol exists in the lumen, the clinically relevant absorptive bottleneck is the NPC1L1 transporter rather than upstream esterase activity.

ANSWER: E

Rationale:

The correct answer is E. The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) was a randomized, double-blind trial that enrolled 18,144 patients who had been hospitalized for acute coronary syndrome within the preceding ten days and had LDL-C between 50 and 100 mg/dL (or up to 125 mg/dL if not on prior lipid therapy). Patients were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. Over a median follow-up of six years, the combination arm achieved a median LDL-C of approximately 54 mg/dL compared with approximately 70 mg/dL in the statin-only arm. The primary composite endpoint — cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke — was reduced by a relative 6.4% (absolute reduction approximately 2%) in the combination arm, a modest but statistically significant result. The trial's critical conceptual contribution was demonstrating that non-statin LDL-C lowering — achieved through a mechanism entirely independent of HMG-CoA reductase inhibition — translates into reduced cardiovascular events. This validated the LDL hypothesis broadly (not just for statins) and supported the principle that lower LDL-C is beneficial regardless of the pharmacological pathway used to achieve it, a principle later reinforced by the FOURIER and ODYSSEY OUTCOMES trials with PCSK9 inhibitors. option are fabricated.

• Option A: Option A is incorrect; IMPROVE-IT did show a statistically significant reduction in MACE — the premise of this option (no event reduction) directly contradicts the trial's findings and represents the incorrect interpretation that was hypothesized by critics before the trial reported.
• Option B: Option B is incorrect; IMPROVE-IT was not a head-to-head comparison of ezetimibe monotherapy versus statin monotherapy — both arms received a statin; ezetimibe was tested as an add-on, not as a standalone alternative.
• Option C: Option C is incorrect; IMPROVE-IT enrolled acute coronary syndrome patients, not stable chronic CAD patients, and did not demonstrate a 32% reduction in events — the actual relative risk reduction was approximately 6.4%; the figures in this
• Option D: Option D is incorrect; IMPROVE-IT enrolled secondary prevention patients with recent ACS, not primary prevention patients with no prior cardiovascular events, and the trial duration was approximately six years of median follow-up, not ten years. CASE 2 A 61-year-old woman with established ASCVD (prior MI two years ago) is on atorvastatin 80 mg daily and ezetimibe 10 mg daily. Her most recent LDL-C is 84 mg/dL. Her cardiologist notes that current ACC/AHA guidelines support further LDL-C lowering in very high-risk secondary prevention patients and discusses adding a PCSK9 inhibitor to her regimen.

ANSWER: C

Rationale:

The correct answer is C. Alirocumab (Praluent) and evolocumab (Repatha) are fully human monoclonal IgG antibodies that target PCSK9 (proprotein convertase subtilisin/kexin type 9), a serine protease secreted by hepatocytes that binds to LDL receptors on the hepatocyte surface and escorts them to lysosomes for degradation. By neutralizing circulating PCSK9 protein before it can bind LDL receptors, these antibodies prevent receptor degradation and allow LDL receptors to recycle back to the hepatocyte surface after each round of LDL particle uptake. The resulting increase in surface LDL receptor density enhances receptor-mediated clearance of LDL-C from plasma, producing LDL-C reductions of 50–60% on top of background statin therapy. Both agents are administered by subcutaneous injection — alirocumab every two weeks (or every four weeks at higher dose) and evolocumab every two weeks or once monthly — and must be refrigerated. As biologic agents (large proteins), they cannot be administered orally because they would be degraded in the gastrointestinal tract.

• Option A: Option A is incorrect; alirocumab and evolocumab are not small-molecule oral inhibitors — they are large monoclonal antibodies that must be injected; no approved oral PCSK9 small-molecule inhibitor existed at the time of their approval, though oral PCSK9 inhibitors (e.g., MK-0616) are in clinical development.
• Option B: Option B is incorrect; the description of antisense oligonucleotides targeting PCSK9 mRNA corresponds to a different drug class — specifically inclisiran, which is an siRNA (small interfering RNA) rather than an antisense oligonucleotide, and which works via the RISC complex rather than RNase H; alirocumab and evolocumab are antibody-based, not nucleic-acid-based.
• Option D: Option D is incorrect; alirocumab and evolocumab are not decoy receptors and do not bind LDL particles directly — they bind PCSK9 protein; a recombinant LDL receptor decoy is a mechanistic concept but does not describe any approved drug.
• Option E: Option E is incorrect; neither alirocumab nor evolocumab is a gene therapy — they are biologic drugs requiring ongoing repeat administration; the description of AAV-mediated LDLR gene delivery corresponds to investigational approaches for homozygous familial hypercholesterolemia, not to currently approved PCSK9 inhibitors.

ANSWER: A

Rationale:

The correct answer is A. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol introduced the concept of "very high-risk" ASCVD — defined as a history of multiple major ASCVD events (recent ACS, history of MI, history of stroke, symptomatic peripheral arterial disease) or one major ASCVD event plus multiple high-risk conditions (age ≥65, heterozygous FH, prior coronary revascularization, diabetes, hypertension, CKD, current smoking, or persistently elevated LDL-C ≥100 mg/dL). For very high-risk patients on maximally tolerated statin therapy with LDL-C at or above 70 mg/dL, the guideline recommends a sequential escalation strategy: first add ezetimibe (Class IIa), and if LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is reasonable (Class IIa). This patient — with prior MI on high-intensity statin plus ezetimibe and LDL-C of 84 mg/dL — meets the guideline criteria for PCSK9 inhibitor consideration. The FOURIER trial (evolocumab) and ODYSSEY OUTCOMES trial (alirocumab) both demonstrated significant reductions in cardiovascular events when PCSK9 inhibitors were added to statin therapy in secondary prevention patients.

• Option B: Option B is incorrect; the ACC/AHA 2018 guideline does not provide a Class I recommendation for PCSK9 inhibitors in all secondary prevention patients with any LDL-C above 55 mg/dL — the recommendation is Class IIa and applies to very high-risk patients with LDL-C ≥70 mg/dL on maximally tolerated statin plus ezetimibe; 55 mg/dL is not the threshold in the 2018 guideline.
• Option C: Option C is incorrect; the guideline does require that maximally tolerated statin therapy (and ezetimibe as an intermediate step) be employed before escalating to PCSK9 inhibitors in secondary prevention; it does not recommend PCSK9 inhibitors as second-line after any statin therapy at any dose.
• Option D: Option D is incorrect; the ACC/AHA 2018 guideline does not restrict PCSK9 inhibitors exclusively to patients with familial hypercholesterolemia — it explicitly addresses PCSK9 inhibitor use in very high-risk secondary prevention patients without FH, and both FOURIER and ODYSSEY OUTCOMES enrolled predominantly non-FH secondary prevention patients.
• Option E: Option E is incorrect; PCSK9 inhibitors do not carry a myopathy risk profile similar to statins — as monoclonal antibodies that act on a circulating extracellular protein, they have no mechanism for causing muscle toxicity; the guideline does not restrict their use to statin-intolerant patients.

ANSWER: E

Rationale:

The correct answer is E. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease synthesized predominantly in hepatocytes and secreted into the circulation. Its role in LDL receptor regulation is post-translational and occurs at the point of receptor trafficking rather than at the transcriptional level. After a hepatocyte LDL receptor binds a circulating LDL particle and the complex is endocytosed, the normal fate is for the LDL particle to be delivered to lysosomes for degradation while the receptor itself is released and recycled to the cell surface — a single LDL receptor can cycle approximately 100–200 times before it is degraded. PCSK9 disrupts this recycling by binding to the EGF-A (epidermal growth factor-like repeat A) domain of the LDL receptor — a binding that is stabilized at the acidic pH of endosomes — so that when the LDL-receptor-PCSK9 complex is endocytosed, the entire complex (receptor included) is routed to lysosomes and degraded rather than the receptor being released and recycled. The net result is reduced steady-state LDL receptor density on the hepatocyte surface and impaired LDL-C clearance. Monoclonal antibody PCSK9 inhibitors (alirocumab, evolocumab) bind circulating PCSK9 before it can interact with the receptor, preserving the normal receptor recycling pathway and increasing functional LDL receptor density. This produces LDL-C reductions of 50–60% on top of background statin therapy.

• Option A: Option A is incorrect; PCSK9 is not a transcription factor and does not suppress LDLR gene transcription — its regulatory role is post-translational, acting on receptor protein trafficking at the lysosomal level rather than at the level of gene expression.
• Option B: Option B is incorrect; PCSK9 is not produced by intestinal enterocytes and does not act through NPC1L1 or portal cholesterol delivery — it is a hepatically secreted protein that acts on LDL receptor trafficking within the hepatocyte endosomal system.
• Option C: Option C is incorrect; PCSK9 does not cleave the extracellular receptor domain — it binds the intact receptor and reroutes it to lysosomes; shedding of soluble LDL receptor fragments does occur physiologically but is not PCSK9's mechanism of action.
• Option D: Option D is incorrect; PCSK9 is not a ubiquitin E3 ligase and does not act primarily in adipocytes — its dominant pharmacologically relevant site of action is the hepatocyte, and its mechanism is lysosomal degradation routing rather than proteasomal ubiquitination.

ANSWER: B

Rationale:

The correct answer is B. Inclisiran (Leqvio) is a double-stranded small interfering RNA (siRNA) that exploits the endogenous RNA interference (RNAi) pathway to silence PCSK9 gene expression in hepatocytes. Unlike alirocumab and evolocumab — which are monoclonal antibodies that neutralize PCSK9 protein after it has been secreted into the circulation — inclisiran acts intracellularly to prevent PCSK9 protein from being synthesized in the first place. The siRNA is conjugated to triantennary N-acetylgalactosamine (GalNAc), a carbohydrate ligand with high-affinity binding to the asialoglycoprotein receptor (ASGPR) expressed almost exclusively on hepatocytes; this conjugation provides precise hepatic targeting and efficient intracellular uptake via receptor-mediated endocytosis. Once inside the hepatocyte, inclisiran is incorporated into the RNA-induced silencing complex (RISC), which uses the siRNA as a template to identify and cleave PCSK9 mRNA — preventing translation of PCSK9 protein. The resulting reduction in PCSK9 secretion allows LDL receptors to recycle normally on the hepatocyte surface, increasing LDL-C clearance by 40–50%. The key clinical advantage of inclisiran is its remarkably infrequent dosing schedule: after initial injections at baseline and three months (during which RISC loading is established), maintenance dosing is only twice yearly — every six months — a substantial convenience advantage over monthly or biweekly monoclonal antibody injections.

• Option A: Option A is incorrect; inclisiran is not an antibody fragment — it is an siRNA molecule; Fab fragments and full-length antibodies are protein-based biologics that work by protein-protein binding, whereas siRNA works through RNA interference within the cell.
• Option C: Option C is incorrect; inclisiran is an siRNA, not an antisense oligonucleotide — these are distinct nucleic acid classes with different mechanisms (RNAi via RISC versus RNase H-mediated degradation); inclisiran also requires GalNAc conjugation for hepatic targeting, which is a central feature of its delivery system.
• Option D: Option D is incorrect; inclisiran is not an oral small molecule — it is an injectable nucleic acid-based biologic; no oral PCSK9-targeting agent targeting autocatalytic cleavage is currently approved.
• Option E: Option E is incorrect; inclisiran is not a CRISPR-Cas9 gene editing agent — it is a reversible RNA silencing agent whose effect depends on ongoing presence of the siRNA-RISC complex and does not permanently alter genomic DNA; CRISPR-based PCSK9 editing (e.g., NTLA-2001) is investigational and has not been approved. CASE 3 A 48-year-old man with type 2 diabetes and obesity presents with a fasting lipid panel showing: TG 680 mg/dL, HDL-C 28 mg/dL, LDL-C (calculated, unreliable at this TG level) 42 mg/dL. He has no prior cardiovascular events. His physician is concerned about acute pancreatitis risk from severe hypertriglyceridemia and initiates pharmacological therapy targeting TG reduction as the immediate priority.

ANSWER: D

Rationale:

The correct answer is D. Fibrates — including fenofibrate, gemfibrozil, and bezafibrate — are agonists of peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated nuclear receptor belonging to the nuclear receptor superfamily. PPARα is expressed at highest levels in tissues with high rates of fatty acid oxidation: liver, skeletal muscle, heart, and kidney. In the liver and vascular endothelium, PPARα activation produces multiple coordinated effects that lower plasma triglycerides: (1) transcriptional upregulation of lipoprotein lipase (LPL), the enzyme responsible for hydrolyzing TG within circulating VLDL and chylomicron particles — increasing the rate of VLDL-TG clearance; (2) reduced hepatic expression of apolipoprotein C-III (apoC-III), a protein that normally inhibits LPL activity and impairs lipoprotein receptor binding — reducing apoC-III allows LPL to work more efficiently and enhances hepatic remnant clearance; (3) increased hepatic fatty acid oxidation via upregulation of genes in the beta-oxidation pathway — reducing the supply of fatty acids available for hepatic TG synthesis and VLDL assembly; and (4) upregulation of apoA-I and apoA-II synthesis, which contributes to the HDL-C raising effect of fibrates (typically 10–20%). The net result is a reduction in plasma TG of 30–50% and a modest increase in HDL-C. In this patient with TG of 680 mg/dL and imminent pancreatitis risk, TG reduction is the therapeutic priority, and fibrate therapy directly addresses the underlying overproduction and impaired clearance of TG-rich lipoproteins.

• Option A: Option A is incorrect; DGAT2 inhibition is the mechanism of volanesorsen (an RNA-based agent targeting apoC-III) and of experimental DGAT2 inhibitors — it is not the mechanism of fibrates; fenofibrate does not directly block TG synthesis via DGAT2.
• Option B: Option B is incorrect; fibrates act primarily through PPARα in the liver and endothelium, not through SREBP-1c activation in adipocytes — SREBP-1c is a lipogenic transcription factor whose activation would increase, not decrease, TG synthesis; this option describes a pharmacologically inverted mechanism.
• Option C: Option C is incorrect; fenofibrate does not inhibit hepatic lipase — this option describes a fabricated mechanism; hepatic lipase inhibition would impair IDL-to-LDL conversion and remnant clearance, which is not the clinical or mechanistic profile of fibrate therapy.
• Option E: Option E is incorrect; ACAT inhibition is not the mechanism of fibrates — ACAT inhibitors (e.g., avasimibe) are investigational compounds that have been studied in atherosclerosis and do not lower TG as their primary effect.

ANSWER: C

Rationale:

The correct answer is C. The pharmacokinetic basis for the inferior safety profile of gemfibrozil-statin combinations compared with fenofibrate-statin combinations lies in gemfibrozil's potent inhibition of two separate transport and metabolic pathways critical to statin disposition. Gemfibrozil and its major metabolite gemfibrozil 1-O-β-glucuronide are potent inhibitors of CYP2C8, an enzyme involved in the oxidative metabolism of several statins (particularly cerivastatin, which was withdrawn from the market partly because of fatal rhabdomyolysis cases in patients also taking gemfibrozil), as well as inhibitors of OATP1B1 (organic anion transporting polypeptide 1B1), a sinusoidal uptake transporter that mediates the hepatic uptake of statin acid forms from portal blood. By inhibiting OATP1B1-mediated hepatic uptake, gemfibrozil increases the systemic plasma concentrations of statin acid forms, which are the pharmacologically active, myotoxic species. When plasma statin acid concentrations rise — particularly in skeletal muscle, which lacks significant drug metabolism capacity — the risk of myopathy and rhabdomyolysis increases dramatically. Fenofibrate does not significantly inhibit either CYP2C8 or OATP1B1 at clinically relevant concentrations, making fenofibrate-statin combinations substantially safer. The FDA label for several statins (simvastatin, lovastatin) includes specific contraindications or warnings for gemfibrozil co-administration.

• Option A: Option A is incorrect; the rationale for preferring fenofibrate over gemfibrozil is a pharmacokinetic safety difference, not a differential effect on VLDL substrate for LDL production — gemfibrozil does not paradoxically raise LDL-C to a clinically relevant degree in this context.
• Option B: Option B is incorrect; while gemfibrozil does form an acyl glucuronide metabolite and this metabolite does inhibit certain UGT isoforms, the primary clinically dangerous interaction is through CYP2C8 inhibition and OATP1B1 inhibition leading to myopathy, not through UGT1A3 inhibition leading to hepatotoxicity.
• Option D: Option D is incorrect; the mechanism of gemfibrozil-statin interaction is not CYP3A4 competition — gemfibrozil itself is not a CYP3A4 inhibitor of clinical significance; the relevant pathway is CYP2C8 and OATP1B1; furthermore, the claim that fenofibrate has no CYP interactions at all overstates the case.
• Option E: Option E is incorrect; gemfibrozil does not directly inhibit HMG-CoA reductase — it is a PPARα agonist, not an HMG-CoA reductase inhibitor; the coenzyme Q10 depletion hypothesis for statin myopathy remains controversial and is not the established mechanistic explanation for gemfibrozil-statin rhabdomyolysis.

ANSWER: A

Rationale:

The correct answer is A. Niacin (nicotinic acid) exerts its primary lipid-modifying effects through the GPR109A receptor (also called HM74A or HCAR2), a Gi-coupled G-protein coupled receptor expressed at high levels on adipocytes and immune cells. Activation of GPR109A in adipocytes inhibits adenylate cyclase, reducing intracellular cAMP and thereby inhibiting hormone-sensitive lipase (HSL) — the key enzyme responsible for lipolysis of stored triglycerides in adipose tissue. The resulting reduction in free fatty acid (FFA) release from adipose tissue decreases portal FFA delivery to the liver, which is the primary substrate for hepatic TG synthesis. With less substrate available, the liver synthesizes fewer TG, assembles fewer VLDL particles, and secretes less VLDL-TG — lowering plasma TG by 20–50%. The reduction in TG-rich VLDL in plasma decreases the activity of cholesteryl ester transfer protein (CETP), which normally exchanges TG from VLDL for cholesteryl esters from HDL — a process that reduces HDL-C mass and creates small, dense LDL particles. With less VLDL-TG substrate available for CETP, HDL particles retain their cholesteryl ester content, and HDL-C rises by 15–35% — the largest HDL-raising effect of any currently available drug. Niacin also reduces hepatic apoB secretion and lowers Lp(a) by 20–30% through mechanisms that are not fully understood. Despite this favorable pharmacological profile, large clinical trials (AIM-HIGH, HPS2-THRIVE) failed to demonstrate incremental cardiovascular event reduction when niacin was added to modern statin therapy, limiting its current clinical use.

• Option B: Option B is incorrect; niacin does not directly inhibit CETP — the reduction in CETP-mediated TG-for-cholesterol exchange is a secondary consequence of reduced VLDL-TG substrate rather than direct enzyme inhibition; CETP inhibitors (anacetrapib, dalcetrapib, torcetrapib) are a distinct pharmacological class.
• Option C: Option C is incorrect; niacin is not a PPARγ agonist — PPARγ activation is the mechanism of thiazolidinediones (pioglitazone, rosiglitazone); niacin's mechanism is GPR109A-mediated adipocyte HSL inhibition.
• Option D: Option D is incorrect; niacin does not directly inhibit DGAT2 — DGAT2 inhibition is a mechanism being pursued in investigational lipid-lowering agents; niacin's primary mechanism is upstream at the level of FFA release from adipose tissue, not at the level of hepatic TG synthesis enzyme inhibition.
• Option E: Option E is incorrect; inhibition of ATP-citrate lyase is the mechanism of bempedoic acid, a recently approved non-statin LDL-lowering agent — it is not the mechanism of niacin, and bempedoic acid acts primarily on LDL-C rather than TG or HDL-C.

ANSWER: E

Rationale:

The correct answer is E. Niacin-induced cutaneous flushing — a sensation of warmth, redness, and pruritus typically affecting the face, neck, and upper chest — occurs in the majority of patients initiating niacin therapy and is the leading cause of drug discontinuation. The mechanism is prostaglandin-mediated: activation of GPR109A receptors on skin-resident Langerhans cells and keratinocytes triggers arachidonic acid mobilization and prostaglandin synthesis via the cyclooxygenase pathway, producing prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2). These prostaglandins act on DP1 receptors (PGD2) and EP2/EP4 receptors (PGE2) on dermal arteriolar smooth muscle, causing vasodilation and the clinical flushing response. Because aspirin inhibits COX-1 and COX-2 — the enzymes required for prostaglandin synthesis from arachidonic acid — pretreatment with aspirin 325 mg approximately 30 minutes before niacin dosing substantially reduces the intensity and duration of flushing. Additional strategies that reduce flushing include gradual dose titration (starting at low doses and incrementing over weeks), taking niacin with food, avoiding hot beverages around dosing time, and using extended-release formulations (which produce lower peak niacin concentrations and reduce the intensity of the flushing stimulus). Notably, laropiprant — a selective DP1 receptor antagonist developed specifically to block PGD2-mediated flushing — was combined with extended-release niacin (Tredaptive) but was withdrawn from development after HPS2-THRIVE showed no cardiovascular benefit of adding niacin/laropiprant to statin therapy.

• Option A: Option A is incorrect; niacin-induced flushing is not mediated by histamine release from mast cells — histamine is not the primary mediator, and antihistamines are not effective at preventing niacin-induced flushing; the mechanism is prostaglandin-mediated through GPR109A on Langerhans cells.
• Option B: Option B is incorrect; niacin metabolites do not activate vascular beta-2 adrenergic receptors — this is a fabricated mechanism; beta-blockade is not an effective or recommended strategy for preventing niacin-induced flushing.
• Option C: Option C is incorrect; the flushing mechanism does involve GPR109A on skin cells and does involve prostaglandin production, but the claim that flushing cannot be prevented pharmacologically is false — aspirin pretreatment demonstrably reduces flushing; the description of "NOS upregulation" as the mechanism is mechanistically inaccurate.
• Option D: Option D is incorrect; niacin does not inhibit 15-hydroxyprostaglandin dehydrogenase (15-PGDH) — this option inverts the mechanism; niacin increases prostaglandin synthesis through COX activation, not by blocking prostaglandin degradation; laropiprant is correctly identified as a DP1 antagonist but the upstream mechanism described is pharmacologically incorrect. CASE 4 A 32-year-old woman is referred to a lipid clinic after a routine lipid panel reveals LDL-C of 338 mg/dL. She has no diabetes, hypertension, or secondary causes of hypercholesterolemia. Her father had a myocardial infarction at age 41. On examination, she has bilateral Achilles tendon xanthomas. Her physician suspects familial hypercholesterolemia (FH).

ANSWER: B

Rationale:

The correct answer is B. Familial hypercholesterolemia (FH) is an autosomal codominant disorder in which a single mutant allele is sufficient to produce a clinically significant elevation in LDL-C. The most common genetic cause — accounting for approximately 85–90% of molecularly confirmed FH cases — is a loss-of-function mutation in the LDLR gene encoding the LDL receptor. Over 2,000 distinct LDLR mutations have been identified, including mutations affecting receptor synthesis, processing, transport to the cell surface, LDL binding, internalization, or receptor recycling. In heterozygotes, who carry one mutant and one normal LDLR allele, LDL receptor activity on hepatocyte surfaces is reduced to approximately 50% of normal. Because the liver is responsible for clearing approximately 70% of circulating LDL-C through LDL receptor-mediated endocytosis, a 50% reduction in receptor activity substantially impairs LDL-C clearance, producing LDL-C levels typically in the range of 190–400 mg/dL — present from birth, because receptor activity (or its absence) is genetically constitutive and not acquired over time. This lifelong LDL-C exposure accelerates atherosclerosis dramatically, with untreated heterozygotes experiencing coronary artery disease two to three decades earlier than the general population. Less common causes of FH include mutations in APOB (which encodes apolipoprotein B-100, the LDL receptor-binding ligand on LDL particles) and gain-of-function mutations in PCSK9 (which increase LDL receptor degradation) — both producing the same downstream phenotype of impaired LDL-C clearance. The bilateral Achilles tendon xanthomas in this patient are a pathognomonic physical finding of FH, reflecting cholesterol deposition from chronically elevated LDL-C in tendon tissue.

• Option A: Option A is incorrect; gain-of-function PCSK9 mutations are a cause of FH but represent only a minority of cases — the most common cause is LDLR loss-of-function mutation; this option also incorrectly frames the mechanism as "overexpression of functional PCSK9" rather than increased PCSK9 activity per protein molecule.
• Option C: Option C is incorrect; apoE2/E2 homozygosity is the basis for type III hyperlipoproteinemia (familial dysbetalipoproteinemia), which causes elevated VLDL remnants and IDL rather than predominantly elevated LDL-C — it is a distinct disorder from FH, and apoE mutations do not cause the classic FH phenotype.
• Option D: Option D is incorrect; ABCA1 loss-of-function mutations cause Tangier disease (very low HDL-C with normal or low LDL-C) — not familial hypercholesterolemia; ABCA1 haploinsufficiency does not produce tendon xanthomas or markedly elevated LDL-C.
• Option E: Option E is incorrect; FH is not caused by HMGCR mutations, and statins remain effective in HeFH — they reduce LDL-C by 40–60% in heterozygotes; the premise that statins are ineffective in FH is pharmacologically incorrect and clinically dangerous if believed.

ANSWER: D

Rationale:

The correct answer is D. Homozygous FH (HoFH) is a severe and rare disorder (prevalence approximately 1 in 300,000–1,000,000) in which both LDLR alleles carry loss-of-function mutations, producing LDL-C levels typically in the range of 400–1,000 mg/dL from birth. Because most statin-mediated LDL-C lowering depends on upregulation of functional LDL receptors via SREBP-2 activation, and because PCSK9 inhibitors act by preventing degradation of LDL receptors that may be minimally functional or absent in HoFH, these agents produce substantially less LDL-C reduction in HoFH than in HeFH or non-FH patients. Treatment therefore requires approaches that lower LDL-C through LDL receptor-independent mechanisms. LDL apheresis — an extracorporeal procedure similar to dialysis that selectively removes apoB-containing lipoproteins from plasma — is the most established approach, typically performed every one to two weeks, and can acutely reduce LDL-C by 60–70%. Lomitapide (Juxtapid) is an oral small-molecule inhibitor of microsomal triglyceride transfer protein (MTP), which is required for loading TG onto nascent apoB-containing lipoproteins in the liver (VLDL) and intestine (chylomicrons); by blocking MTP, lomitapide reduces VLDL and chylomicron assembly and secretion, lowering LDL-C by 40–50% independently of LDL receptor activity. Evinacumab (Evkeeza) is a fully human monoclonal antibody targeting ANGPTL3 (angiopoietin-like protein 3), which normally inhibits both lipoprotein lipase (LPL) and endothelial lipase (EL); by inhibiting ANGPTL3, evinacumab restores LPL and EL activity, accelerating clearance of TG-rich lipoproteins and their remnants and ultimately lowering LDL-C by a receptor-independent mechanism; it is the first LDL-lowering therapy specifically approved for HoFH that works regardless of residual LDL receptor function.

• Option A: Option A is incorrect; simultaneous administration of both alirocumab and evolocumab is not an approved or evidence-based strategy — PCSK9 antibody dual therapy provides no additional benefit over a single agent because both antibodies compete for the same PCSK9 target; furthermore, in HoFH patients with minimal or no functional LDL receptors, PCSK9 inhibitors provide very limited LDL-C reduction.
• Option B: Option B is incorrect; while AAV8-mediated LDLR gene therapy is an area of active clinical research for HoFH, it has not received full FDA approval as of the current evidence base and does not represent a standard treatment option.
• Option C: Option C is incorrect; niacin and omega-3 fatty acids do not produce 40–50% LDL-C reduction in HoFH and are not approved or recommended as alternatives to apheresis in HoFH; niacin lowers LDL-C modestly (10–20%) and its effect depends partly on receptor-mediated clearance.
• Option E: Option E is incorrect; bile acid sequestrants partially depend on LDL receptor upregulation (their mechanism drives compensatory receptor expression via SREBP-2) and do not achieve 50–60% LDL-C reduction in HoFH; they are not preferred over apheresis for severe HoFH and can raise TG, which is particularly concerning in patients with already elevated TG.

ANSWER: C

Rationale:

The correct answer is C. The Fredrickson-Levy-Lees classification (adopted by the WHO) categorizes hyperlipoproteinemia phenotypes by the specific lipoprotein class or classes that are elevated on electrophoresis or ultracentrifugation. Type IIa is defined by isolated elevation of LDL-C (the beta-lipoprotein band on electrophoresis) with normal TG and normal VLDL — precisely the profile seen in this patient with LDL-C of 338 mg/dL and no hypertriglyceridemia. Type IIa can be familial (most commonly FH due to LDLR mutations, or familial defective apoB-100) or secondary (hypothyroidism, nephrotic syndrome, cholestasis). Type IIb — the adjacent phenotype most frequently confused with Type IIa — is characterized by concurrent elevation of both LDL-C (beta band) and VLDL-C (pre-beta band), producing combined hypercholesterolemia and hypertriglyceridemia; familial combined hyperlipidemia (FCHL) typically presents as Type IIb. The clinical distinction matters because Type IIb patients require therapy targeting both LDL-C (statins, ezetimibe) and TG (fibrates, omega-3 fatty acids), whereas Type IIa patients need only LDL-C-directed therapy. This patient's normal TG, absent VLDL elevation, and markedly elevated LDL-C in the context of tendon xanthomas, a strong family history of premature CAD, and LDL-C of 338 mg/dL is classic for Type IIa FH.

• Option A: Option A is incorrect; Type I hyperlipoproteinemia is characterized by chylomicronemia due to LPL deficiency or apoC-II deficiency — it presents with very high TG (often >1,000 mg/dL), eruptive xanthomas, and recurrent pancreatitis; LDL-C is typically normal or low, not markedly elevated; this is the wrong phenotype entirely.
• Option B: Option B is incorrect; Type IV is characterized by isolated VLDL elevation with hypertriglyceridemia and normal LDL-C — the opposite of this patient's profile; the suggestion that LDL-C elevation in this case is a Friedewald calculation artifact is implausible given the degree of elevation (338 mg/dL) and the clinical context of FH.
• Option D: Option D is incorrect; Type III (familial dysbetalipoproteinemia) is characterized by IDL accumulation due to apoE2/E2 homozygosity and presents with both elevated cholesterol and TG, with palmar xanthomas (xanthoma striata palmaris) as a distinctive finding rather than Achilles tendon xanthomas; the patient's normal TG and tendon xanthomas are inconsistent with Type III.
• Option E: Option E is incorrect; this option correctly identifies the distinction between IIa and IIb but then misapplies it by claiming FH typically presents as IIb — FH (LDLR mutation) classically presents as Type IIa with isolated LDL-C elevation and normal TG; it is familial combined hyperlipidemia (FCHL, a different genetic disorder) that typically presents as Type IIb.

ANSWER: A

Rationale:

The correct answer is A. Bile acid sequestrants — including cholestyramine, colestipol, and colesevelam — are non-absorbable, positively charged (cationic) polymer resins or gels that remain entirely in the gastrointestinal lumen after oral administration. In the intestinal lumen, they electrostatically bind negatively charged bile acids (which are amphipathic steroid derivatives conjugated to glycine or taurine), physically sequestering them and preventing their active reabsorption by the ileal bile acid transporter (ASBT/SLC10A2) in the terminal ileum. Normally, 95% of secreted bile acids are reabsorbed in the terminal ileum and returned to the liver via the portal circulation (enterohepatic recirculation), where they are re-secreted into bile — a pool-conserving cycle. When resins interrupt this cycle, fecal bile acid excretion increases, and the hepatic bile acid pool is depleted. This deficit activates CYP7A1 (cholesterol 7-alpha-hydroxylase), the rate-limiting enzyme that converts cholesterol to primary bile acids, increasing cholesterol-to-bile-acid conversion. The resulting reduction in intrahepatic cholesterol activates SREBP-2, which upregulates LDL receptor expression on the hepatocyte surface, enhancing receptor-mediated LDL-C clearance from plasma. Bile acid sequestrants reduce LDL-C by approximately 15–25% as monotherapy. An important limitation: because upregulated LDL receptor expression also increases VLDL remnant uptake and subsequent VLDL-to-LDL conversion is increased, some patients — particularly those with pre-existing hypertriglyceridemia — experience TG elevation on bile acid sequestrant therapy; for this reason, older resins (cholestyramine, colestipol) are relatively contraindicated in patients with TG above 300–400 mg/dL. Colesevelam, the newest resin, also has FDA approval for glucose lowering in type 2 diabetes, likely via TGR5-mediated GLP-1 effects, and does not raise TG to the same degree as older resins.

• Option B: Option B is incorrect; the description of small-molecule IBAT inhibitors corresponds to a distinct pharmacological class (e.g., odevixibat, used in pediatric cholestatic liver disease) — not to bile acid sequestrants; classic resins such as cholestyramine are large polymer molecules that are never absorbed.
• Option C: Option C is incorrect; bile acid sequestrants do not directly antagonize FXR (the farnesoid X receptor) — they work by physically binding bile acids in the gut lumen rather than by competing with bile acids at FXR; while the downstream consequence includes reduced FXR activation (because the hepatic bile acid pool is depleted), the mechanism is physical sequestration in the lumen, not intrahepatic FXR antagonism.
• Option D: Option D is incorrect; bile acid sequestrants are not absorbed from the intestine — they are designed to be entirely non-absorbable, which is what makes them pharmacologically safe with minimal systemic toxicity; they do not reach the liver or inhibit NTCP.
• Option E: Option E is incorrect; while TGR5 activation by bile acids does stimulate GLP-1 secretion from enteroendocrine cells and may contribute to colesevelam's glucose-lowering effect, this is not the primary mechanism of LDL-C reduction — the primary mechanism is enterohepatic recirculation interruption with compensatory hepatic LDL receptor upregulation; furthermore, this option describes a mechanism that would apply only to colesevelam's glucose-lowering effect, not to bile acid sequestrant LDL-C reduction as a class. CASE 5 A 58-year-old man with a 10-year ASCVD risk of 11% is being evaluated for statin initiation. He has no prior cardiovascular events, no diabetes, and no familial hypercholesterolemia. His LDL-C is 158 mg/dL. His physician discusses statin intensity selection and the ACC/AHA 2018 guideline framework for treatment decisions.

ANSWER: E

Rationale:

The correct answer is E. The ACC/AHA classification of statin intensity is based on the expected percentage reduction in LDL-C from baseline, not on absolute LDL-C achieved or on pharmacokinetic properties. High-intensity statins are defined as those expected to lower LDL-C by 50% or more; the two regimens that consistently meet this threshold in clinical trials are atorvastatin 40 mg and 80 mg (the most commonly prescribed high-intensity agents) and rosuvastatin 20 mg and 40 mg. Moderate-intensity regimens are expected to lower LDL-C by 30–49% and include atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg, pravastatin 40–80 mg, lovastatin 40 mg, fluvastatin 80 mg (XL), and pitavastatin 2–4 mg. Low-intensity regimens lower LDL-C by less than 30%. The 2018 ACC/AHA guideline recommends high-intensity statin therapy for: (1) patients with clinical ASCVD (secondary prevention), (2) patients with LDL-C ≥190 mg/dL (including FH), and (3) patients aged 40–75 with diabetes and 10-year ASCVD risk ≥20%. For this patient — a primary prevention patient with 11% 10-year risk — moderate- to high-intensity statin therapy is reasonable following a risk discussion, but the automatic indication for high-intensity is not triggered by risk alone at 11%; high-intensity is preferred when risk is ≥20% or additional high-risk features are present.

• Option A: Option A is incorrect; simvastatin 80 mg is not recommended by the ACC/AHA — the FDA and ACC/AHA both advise against initiating simvastatin 80 mg due to its unacceptably high myopathy risk compared with alternative high-intensity agents; it is not listed as a preferred high-intensity agent, and the doses listed in this option for atorvastatin and rosuvastatin are moderate-, not high-intensity doses.
• Option B: Option B is incorrect; atorvastatin 10–20 mg and rosuvastatin 5–10 mg are moderate-intensity regimens, not high-intensity; statin intensity is classified by LDL-C reduction magnitude, not by pharmacokinetic properties such as half-life or hepatoselectivity.
• Option C: Option C is incorrect; statin intensity is classified by expected percentage LDL-C reduction from baseline, not by absolute LDL-C achieved — the same absolute LDL-C of 65 mg/dL could result from high-intensity statin in a patient with baseline LDL-C of 130 mg/dL (50% reduction) or from a moderate-intensity statin in a patient with baseline 90 mg/dL (28% reduction, which would be low-intensity by the percentage definition).
• Option D: Option D is incorrect; the doses listed — simvastatin 40 mg, atorvastatin 10 mg, rosuvastatin 5 mg — are moderate-intensity regimens, not high-intensity; the description of these as "the highest intensities recommended" misrepresents the ACC/AHA classification.

ANSWER: C

Rationale:

The correct answer is C. Statins differ substantially in their dependence on cytochrome P450 enzymes for metabolism, and this difference has direct clinical relevance for drug-drug interaction management. Simvastatin and lovastatin — both lactone prodrugs — are highly susceptible to CYP3A4-mediated interactions: they undergo extensive first-pass CYP3A4 metabolism in the intestinal wall and liver, and CYP3A4 inhibitors (including diltiazem, verapamil, erythromycin, clarithromycin, itraconazole, ketoconazole, and grapefruit juice constituents) substantially increase their plasma concentrations, raising myopathy risk. The FDA has established dose caps for simvastatin when used with certain CYP3A4 inhibitors (e.g., simvastatin 10 mg maximum with diltiazem or amiodarone). Atorvastatin is also a CYP3A4 substrate and interacts with CYP3A4 inhibitors, but its longer half-life, lower first-pass extraction relative to simvastatin/lovastatin, and additional metabolic pathways result in a quantitatively less severe interaction in many cases — though care is still warranted. In contrast, rosuvastatin undergoes minimal CYP-mediated metabolism (it is a minor CYP2C9 substrate but not meaningfully metabolized by CYP3A4) and is not susceptible to CYP3A4 inhibitor interactions. Pravastatin undergoes hepatic sulfation and glucuronidation rather than significant CYP metabolism and is similarly resistant to CYP3A4 inhibition. Pitavastatin is primarily metabolized by UGT1A3 and UGT2B7 (glucuronidation) with minor CYP2C9 contribution and is also minimally susceptible to CYP3A4 interactions. For this patient taking diltiazem, rosuvastatin or pravastatin represent the safest statin choices from a drug-interaction standpoint.

• Option A: Option A is incorrect; not all statins are metabolized exclusively by CYP3A4 — rosuvastatin, pravastatin, and pitavastatin have minimal CYP3A4 involvement; furthermore, CYP3A4 affinity (Km) does not work in the direction described: a lower Km (higher affinity) enzyme substrate would be more, not less, susceptible to competitive inhibition.
• Option B: Option B is incorrect; rosuvastatin and pravastatin are not primarily metabolized by CYP2C9 — rosuvastatin is a minor CYP2C9 substrate and pravastatin is primarily glucuronidated; the assertion that they are at higher risk from diltiazem than simvastatin inverts the correct clinical guidance.
• Option D: Option D is incorrect; pitavastatin and fluvastatin are not the most CYP3A4-susceptible statins — simvastatin and lovastatin carry the highest CYP3A4 interaction risk; furthermore, the prodrug activation step for simvastatin and lovastatin (hydrolysis of the lactone ring) does not protect them from CYP3A4 inhibition because CYP3A4 metabolism occurs after activation.
• Option E: Option E is incorrect; atorvastatin is not the only CYP3A4-interacting statin — simvastatin and lovastatin carry even greater CYP3A4 interaction risk; furthermore, atorvastatin is administered as its active acid form, not as a prodrug requiring CYP3A4 bioactivation; simvastatin and lovastatin are the lactone prodrugs.

ANSWER: B

Rationale:

The correct answer is B. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol identifies four groups in whom randomized controlled trial evidence most robustly supports statin therapy for cardiovascular risk reduction. The first group comprises adults with clinical ASCVD — including history of acute coronary syndrome, prior MI, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin — for whom statins are indicated as secondary prevention regardless of baseline LDL-C. The second group comprises adults with primary severe hypercholesterolemia defined by LDL-C ≥190 mg/dL (characteristic of familial hypercholesterolemia or severe polygenic hypercholesterolemia), for whom high-intensity statin therapy is recommended without formal risk calculation because the lifetime cardiovascular risk burden is established by the LDL-C elevation itself. The third group comprises adults aged 40–75 with diabetes mellitus, in whom moderate-intensity statin therapy is recommended for all patients and high-intensity statin therapy for those with additional risk factors or calculated 10-year ASCVD risk ≥20%. The fourth group comprises adults aged 40–75 without diabetes or clinical ASCVD who have a 10-year ASCVD risk of 7.5% or greater using the Pooled Cohort Equations — a group in whom statin initiation is supported after a clinician-patient risk discussion (risk discussion explicitly required by the 2018 guideline) that incorporates risk-enhancing factors, coronary artery calcium scoring where appropriate, patient preferences, and safety considerations. This patient — a 58-year-old with 11% 10-year risk and no diabetes or ASCVD — falls in the fourth group.

• Option A: Option A is incorrect; the ACC/AHA 2018 guideline does not define statin benefit groups by LDL-C above 130 mg/dL plus risk above 5%, by metabolic syndrome, or by age above 60 with hypertension; metabolic syndrome components are listed as risk-enhancing factors but do not constitute an independent statin benefit group.
• Option C: Option C is incorrect; the guideline does not define all adults above age 50 as a statin benefit group; family history of premature CAD is a risk-enhancing factor in the 2018 guideline, not a primary benefit group criterion; and the LDL-C threshold that defines the second benefit group is ≥190 mg/dL, not ≥160 mg/dL.
• Option D: Option D is incorrect; the LDL-C threshold for the second benefit group is ≥190 mg/dL, not ≥160 mg/dL; the 10-year risk threshold for the fourth group is ≥7.5%, not >10%; CKD is a risk-enhancing factor in the 2018 guideline but does not constitute an independent statin benefit group.
• Option E: Option E is incorrect; the ACC/AHA 2018 guideline does not define statin benefit groups solely on a continuous risk-threshold scale — the four groups are defined by clinical category (ASCVD, LDL-C ≥190, diabetes, or calculated risk ≥7.5%), not by a single stratified risk ladder; patients with ASCVD or LDL-C ≥190 mg/dL are not classified by the Pooled Cohort Equations.

ANSWER: D

Rationale:

The correct answer is D. The ACC/AHA 2018 Guideline introduced the concept of risk-enhancing factors as clinical features that increase cardiovascular risk beyond what the Pooled Cohort Equations capture — particularly relevant for the approximately one-third of intermediate-risk patients (10-year risk 7.5–20%) for whom the net benefit of statin therapy is less certain. When an intermediate-risk patient has one or more risk-enhancing factors, the guideline recommends that this information be incorporated into the clinician-patient risk discussion and generally favors statin initiation. The list of ACC/AHA-recognized risk-enhancing factors is comprehensive and includes: family history of premature ASCVD (first-degree male relative with event before age 55 or female relative before age 65); primary hypercholesterolemia (LDL-C 160–189 mg/dL or non-HDL-C 190–219 mg/dL); metabolic syndrome (a cluster of abdominal obesity, elevated TG, low HDL-C, hypertension, and elevated fasting glucose); chronic kidney disease (not on dialysis or renal replacement therapy); chronic inflammatory conditions including rheumatoid arthritis, psoriasis, and HIV/AIDS; history of premature menopause (before age 40) or history of pregnancy-associated hypertension or preeclampsia; high-risk ethnicity (South Asian ancestry); persistently elevated TG ≥175 mg/dL; and biomarkers: Lp(a) ≥50 mg/dL (mg/dL nmol/L conversion applies), hs-CRP ≥2.0 mg/L, and ABI <0.9.

• Option A: Option A is incorrect; isolated systolic hypertension in adults above age 70 is not listed as a separate risk-enhancing factor in the 2018 guideline — hypertension is a component of the Pooled Cohort Equations and of metabolic syndrome, but isolated systolic hypertension in the elderly is not a stand-alone risk-enhancing factor.
• Option B: Option B is incorrect; family history of premature ASCVD is explicitly listed as a risk-enhancing factor in the 2018 guideline — the statement that it is already captured in the Pooled Cohort Equations is incorrect; family history is not a variable in the standard PCE algorithm, which is why it remains a clinically additive risk-enhancing factor.
• Option C: Option C is incorrect; CAC scoring is specifically distinguished from risk-enhancing factors in the 2018 guideline — CAC is classified as a decision aid for use when the statin initiation decision remains uncertain after risk-enhancing factors are considered; a CAC score above 100 or above the 75th percentile generally favors statin therapy but the guideline does not reclassify CAC as a risk-enhancing factor, and a positive CAC score does not bypass the risk discussion requirement.
• Option E: Option E is incorrect; non-HDL-C ≥190 mg/dL and persistently elevated TG ≥175 mg/dL are both listed as risk-enhancing factors in the 2018 guideline; the claim that non-HDL-C is exclusively used when LDL-C is unreliable misrepresents the guideline's use of non-HDL-C as an independent risk metric. CASE 6 A 55-year-old man with type 2 diabetes is on atorvastatin 40 mg daily with LDL-C well controlled at 62 mg/dL. His fasting TG is persistently elevated at 310 mg/dL despite dietary modification. His HDL-C is 34 mg/dL. His physician considers adding omega-3 fatty acid therapy and discusses the clinical trial evidence supporting this approach.

ANSWER: A

Rationale:

The correct answer is A. The REDUCE-IT trial (Reduction of Cardiovascular Events with Icosapentaenoic Acid — Intervention Trial) was a randomized, double-blind, placebo-controlled trial that enrolled 8,179 patients with established atherosclerotic cardiovascular disease or diabetes mellitus plus at least two additional cardiovascular risk factors. All patients had fasting TG between 135 and 499 mg/dL and were on stable statin therapy with LDL-C between 40 and 100 mg/dL — representing the "residual hypertriglyceridemia despite statin therapy" phenotype that is common in patients with diabetes and metabolic syndrome. Patients were randomized to icosapentaenoic acid (EPA) ethyl ester (Vascepa) 2 grams twice daily (4 grams daily total) or mineral oil capsules as placebo. Over a median follow-up of 4.9 years, the primary composite endpoint — a five-point MACE composite including cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, and hospitalization for unstable angina — was reduced by a relative 25% and an absolute 4.8 percentage points in the EPA group. Importantly, the degree of cardiovascular event reduction substantially exceeded what would be predicted from the 18–19% TG reduction alone, suggesting that EPA's cardiovascular benefit involves mechanisms beyond TG lowering — including reduction of platelet aggregation, improvement in endothelial function, stabilization of atherosclerotic plaques, and anti-inflammatory effects. The choice of mineral oil as the placebo was subsequently criticized because mineral oil may have raised LDL-C and hs-CRP in the placebo group, potentially exaggerating the apparent treatment benefit.

• Option B: Option B is incorrect; REDUCE-IT used EPA ethyl ester (Vascepa, a pure EPA formulation) — not a combined EPA plus DHA formulation (Lovaza); it enrolled patients with elevated TG (135–499 mg/dL), not normal TG; and all patients were on background statin therapy.
• Option C: Option C is incorrect; REDUCE-IT was not a head-to-head comparison against fenofibrate — it compared EPA versus mineral oil placebo; severe hypertriglyceridemia (TG above 500 mg/dL) was an exclusion criterion, not an enrollment criterion.
• Option D: Option D is incorrect; the description of omega-3 carboxylic acids (Epanova) versus olive oil in REDUCE-IT is incorrect — that description corresponds to the STRENGTH trial (which did show no benefit with combined EPA/DHA omega-3 carboxylic acids), not to REDUCE-IT; the conflation of these two trials is a common and pharmacologically important error.
• Option E: Option E is incorrect; REDUCE-IT enrolled patients on background statin therapy and used pure EPA ethyl ester, not combined EPA plus DHA Lovaza; the benefit in REDUCE-IT was not restricted to the TG above 400 mg/dL subgroup.

ANSWER: E

Rationale:

The correct answer is E. While moderately elevated TG (175–499 mg/dL) is associated with increased cardiovascular risk and warrants attention (and is a risk-enhancing factor per the ACC/AHA 2018 guideline), the clinical urgency of TG management changes qualitatively when TG exceeds 500 mg/dL and particularly when it exceeds 1,000 mg/dL. At these levels, the primary clinical concern shifts from cardiovascular risk to acute pancreatitis — a potentially life-threatening complication. The mechanism of hypertriglyceridemia-induced pancreatitis involves accumulation of chylomicrons and TG-rich VLDL particles that exceed the clearance capacity of lipoprotein lipase; these large TG-rich particles enter the pancreatic microcirculation, where pancreatic lipase hydrolyzes them to free fatty acids at concentrations that exceed albumin-binding capacity, causing direct acinar cell toxicity, lipid microthrombi formation, and local ischemia. Hypertriglyceridemia accounts for approximately 1–4% of acute pancreatitis cases (after gallstones and alcohol), and the risk rises substantially above TG of 1,000 mg/dL. Treatment priorities include strict dietary fat restriction (less than 10–15% of calories from fat acutely), abstinence from alcohol, fibrates (which reduce TG by 30–50% via PPARα-mediated LPL upregulation), high-dose omega-3 fatty acids, and identification and treatment of secondary causes (diabetes, hypothyroidism, excessive alcohol intake, medications). In acute hypertriglyceridemia-induced pancreatitis, plasmapheresis or insulin infusion may be used to rapidly lower TG.

• Option A: Option A is incorrect; TG above 200 mg/dL does not trigger pancreatitis risk or require fibrate as the immediate primary priority — TG in the 200–499 mg/dL range is concerning and warrants lifestyle modification and possibly pharmacological therapy, but the urgency does not override statin-first prioritization for cardiovascular risk at this level.
• Option B: Option B is incorrect; TG above 150 mg/dL is classified as borderline-high rather than high in ACC/AHA nomenclature, and it does not constitute an independent statin benefit group — it is a risk-enhancing factor when persistent; the claim of relative risk comparable to LDL-C is an overstatement.
• Option C: Option C is incorrect; the threshold for pancreatitis risk is approximately 500 mg/dL (and rises markedly above 1,000 mg/dL), not 300 mg/dL; the claim that fibrate therapy is recommended primarily to prevent NAFLD rather than pancreatitis at the 300 mg/dL threshold misrepresents the clinical evidence and guideline recommendations.
• Option D: Option D is incorrect; the clinical urgency of TG above 1,000 mg/dL is the risk of acute pancreatitis, not the Friedewald equation becoming unreliable — while it is true that Friedewald-calculated LDL-C is inaccurate when TG is markedly elevated (and may approach zero or become negative), this is a laboratory limitation, not the primary clinical concern driving urgent TG management.

ANSWER: C

Rationale:

The correct answer is C. Dietary lipids absorbed in the small intestine are packaged by enterocytes into chylomicrons — large TG-rich lipoprotein particles (80–1,200 nm in diameter) carrying apolipoprotein B-48 as their structural protein. Unlike VLDL, which is secreted by hepatocytes into the portal circulation, chylomicrons are secreted into intestinal lymphatic vessels (lacteals) and travel through the thoracic duct, entering the systemic bloodstream at the left subclavian vein — a routing that bypasses hepatic first-pass processing. Once in the systemic circulation, chylomicrons acquire apolipoprotein C-II (apoC-II) from HDL particles; apoC-II is the obligate activator of lipoprotein lipase (LPL), a serine lipase anchored to the luminal (intravascular) surface of capillary endothelium via heparan sulfate proteoglycan binding. LPL hydrolyzes the fatty acids from the TG core of chylomicrons, releasing free fatty acids that are taken up by adipocytes (for storage as TG) and skeletal and cardiac muscle (for beta-oxidation as energy substrate). The progressive TG hydrolysis shrinks the chylomicron and releases surface components (phospholipids, cholesterol, apoC-II, and apoA-I) to HDL particles; the residual cholesterol-enriched, TG-depleted particle is the chylomicron remnant, which retains apoE. Remnant particles are cleared from the circulation by the liver, where apoE mediates binding to LDL receptors and to LRP1 (low-density lipoprotein receptor-related protein 1) in the space of Disse. Fibrates increase LPL expression via PPARα, accelerating the rate of TG hydrolysis in chylomicrons and VLDL and explaining their primary TG-lowering mechanism.

• Option A: Option A is incorrect; chylomicrons are assembled by intestinal enterocytes, not hepatocytes, and they enter the circulation via the thoracic duct lymphatic system, not the hepatic veins; hepatic lipase acts on chylomicron remnants and IDL but not on intact circulating chylomicrons.
• Option B: Option B is incorrect; chylomicrons are assembled by enterocytes, not hepatocytes, and are secreted into intestinal lymphatics, not the portal circulation; intact chylomicrons are not taken up by VLDL receptors in peripheral tissue — TG hydrolysis by LPL occurs in the capillary lumen before fatty acid uptake.
• Option D: Option D is incorrect; chylomicrons enter the systemic circulation via the thoracic duct, not the portal circulation; LPL is the primary enzyme for chylomicron TG hydrolysis in peripheral capillaries — this is not a hepatic lipase function; and LPL does access chylomicrons in capillary beds without pre-processing by hepatic lipase.
• Option E: Option E is incorrect; chylomicrons are synthesized by intestinal enterocytes, not hepatocytes — hepatocytes produce VLDL; while it is correct that chylomicrons carry apoB-48 (produced by intestinal apoB mRNA editing) and VLDL carries apoB-100 (full-length hepatic apoB), the claim that these two particle types are processed identically by LPL is an oversimplification — their metabolic fates differ substantially after LPL hydrolysis, with VLDL remnants (IDL) being converted to LDL while chylomicron remnants are cleared directly by the liver.

ANSWER: B

Rationale:

The correct answer is B. Bempedoic acid (Nexletol) is an oral non-statin LDL-lowering agent that inhibits ATP-citrate lyase (ACL, also called ACLY), an enzyme that catalyzes the conversion of mitochondrial citrate to cytoplasmic acetyl-CoA and oxaloacetate. Cytoplasmic acetyl-CoA is the primary carbon source for both de novo fatty acid synthesis and cholesterol synthesis via the mevalonate pathway — making ACL a point upstream of HMG-CoA reductase. By reducing cytoplasmic acetyl-CoA availability, bempedoic acid impairs hepatic cholesterol synthesis, reduces intrahepatic cholesterol, and triggers compensatory SREBP-2-mediated LDL receptor upregulation — the same downstream consequence as statins, achieved via a different upstream enzyme. The critical pharmacological feature distinguishing bempedoic acid from statins with respect to muscle toxicity is its prodrug design: bempedoic acid requires bioactivation by very long-chain acyl-CoA synthetase 1 (ACSVL1), an enzyme that is expressed in the liver but is absent or expressed at negligible levels in skeletal muscle. Consequently, bempedoic acid is converted to its pharmacologically active form in the liver (where it inhibits ACL and lowers cholesterol synthesis) but remains in its inactive prodrug form in skeletal muscle — preventing any ACL inhibition in muscle tissue and eliminating the myopathy risk associated with the mechanism. In clinical trials (CLEAR Harmony, CLEAR Serenity, CLEAR Outcomes), bempedoic acid reduced LDL-C by approximately 15–25% and demonstrated cardiovascular event reduction in statin-intolerant patients in the CLEAR Outcomes trial. Notable adverse effect: bempedoic acid raises uric acid and is associated with a small increase in gout risk.

• Option A: Option A is incorrect; bempedoic acid does not inhibit PCSK9 secretion or autocatalytic cleavage — PCSK9 inhibition is the mechanism of monoclonal antibodies (alirocumab, evolocumab) and siRNA (inclisiran), not of bempedoic acid; bempedoic acid acts on ATP-citrate lyase in the cholesterol biosynthesis pathway.
• Option C: Option C is incorrect; squalene synthase inhibition is the mechanism of lapaquistat and other investigational agents, not of bempedoic acid; bempedoic acid acts at ACL, not at squalene synthase; furthermore, bempedoic acid IS a prodrug requiring ACSVL1 activation, which is a pharmacologically important distinction.
• Option D: Option D is incorrect; bempedoic acid does not inhibit the ileal bile acid transporter — that mechanism describes IBAT inhibitors (e.g., odevixibat); bempedoic acid acts within hepatocytes on the mevalonate pathway, not in the intestine on bile acid transport.
• Option E: Option E is incorrect; bempedoic acid does not inhibit fatty acid synthase — FASN inhibition is a separate investigational strategy; bempedoic acid's mechanism is ACL inhibition, reducing acetyl-CoA availability as the common precursor to both fatty acid and cholesterol synthesis, which secondarily reduces both pathways rather than selectively rerouting acetyl-CoA between them. CASE 7 A 67-year-old woman with chronic kidney disease (CKD) stage 3b (eGFR 38 mL/min/1.73m²), hypertension, and no prior cardiovascular events presents for a medication review. Her LDL-C is 142 mg/dL and her 10-year ASCVD risk is 18%. Her nephrologist asks the general internist to recommend statin therapy and to select an agent appropriate for her level of renal function.

ANSWER: D

Rationale:

The correct answer is D. Statin selection in CKD requires consideration of the pharmacokinetic properties of each agent — specifically, the extent to which the parent drug and its active metabolites depend on renal elimination. Pravastatin is eliminated primarily in the feces (approximately 70%) with a smaller fraction excreted renally; it does not require dose adjustment in CKD and is considered among the safer statins in renal impairment. Fluvastatin is extensively metabolized by CYP2C9 to inactive metabolites and excreted predominantly in feces (approximately 90%); it also does not require dose adjustment in CKD. Atorvastatin and its active metabolites are predominantly eliminated via biliary excretion, and the drug is generally considered acceptable across all CKD stages without mandatory dose adjustment, though caution at high doses in severe CKD is reasonable. Rosuvastatin undergoes more significant renal excretion than the other statins — approximately 28% is excreted unchanged in urine — and the prescribing information recommends a starting dose of 5 mg daily (maximum 10 mg daily) in patients with severe CKD (eGFR below 30 mL/min/1.73m²) and in patients on hemodialysis. High-dose simvastatin (80 mg) is specifically associated with an unacceptably high rate of myopathy and rhabdomyolysis in CKD patients and should be avoided regardless of renal function; CKD itself is an independent risk factor for statin-associated myopathy because reduced renal clearance of statin metabolites increases systemic drug exposure. For this patient with CKD stage 3b and 18% 10-year ASCVD risk, atorvastatin at a moderate dose or pravastatin are reasonable choices.

• Option A: Option A is incorrect; statins are not all equally safe in CKD — rosuvastatin requires dose adjustment in severe CKD, high-dose simvastatin carries excess myopathy risk in CKD, and CKD independently increases myopathy risk with any statin by reducing drug clearance; the claim that all statins are free from renal dosing considerations is pharmacologically inaccurate.
• Option B: Option B is incorrect; atorvastatin does not penetrate renal tubular epithelial cells to reduce tubular inflammation as a separate nephroprotective mechanism distinct from its LDL-C-lowering effect — this is a fabricated mechanism; while statins may have pleiotropic anti-inflammatory effects, there is no basis for claiming that high-intensity atorvastatin is uniquely indicated in CKD due to renal tubular penetration.
• Option C: Option C is incorrect; rosuvastatin is not absolutely contraindicated in all patients with eGFR below 60 mL/min/1.73m² — dose reduction to 5 mg maximum is recommended in severe CKD (eGFR below 30 mL/min/1.73m²) and in dialysis patients; the label does not recommend discontinuation at eGFR below 30; the stated renal elimination fraction of 90% is grossly overstated (actual renal excretion is approximately 28%).
• Option E: Option E is incorrect; simvastatin is not eliminated by hepatic glucuronidation to a renally excreted inactive conjugate — it is metabolized by CYP3A4, and high-dose simvastatin (80 mg) is specifically flagged as carrying excess myopathy risk in CKD; pravastatin does not accumulate as a toxic active compound in renal failure.

ANSWER: C

Rationale:

The correct answer is C. Drug-induced dyslipidemia is a clinically important consideration in patients on chronic medication therapy. Glucocorticoids produce a mixed dyslipidemia through several mechanisms: they stimulate hepatic VLDL-TG production (by increasing hepatic lipogenesis and by driving peripheral lipolysis via hormone-sensitive lipase activation in adipose tissue, which releases FFA into the portal circulation and provides substrate for VLDL-TG assembly), raise LDL-C (via increased VLDL-to-LDL conversion and impaired LDL receptor-mediated clearance), and may reduce HDL-C with chronic use; they also contribute to insulin resistance, which further exacerbates hypertriglyceridemia. The degree of lipid effect is generally dose-dependent and duration-dependent, but clinically meaningful TG and LDL-C elevations can occur at relatively modest doses (10 mg prednisone daily) with chronic use. Thiazide diuretics (hydrochlorothiazide, chlorthalidone) cause mild, transient increases in total cholesterol, LDL-C, and TG — effects that are most prominent in the first months of therapy and tend to attenuate over one to two years of continued use; the clinical significance of thiazide-induced lipid changes is generally considered modest in the context of their cardiovascular benefits. Atypical antipsychotics — particularly clozapine, olanzapine, and to a lesser extent quetiapine — are associated with marked hypertriglyceridemia and weight gain; the mechanisms include histamine H1 receptor antagonism (increasing appetite and weight gain), muscarinic M3 receptor antagonism (impairing glucose-stimulated insulin secretion and contributing to insulin resistance), and direct effects on adipogenesis; the resulting metabolic syndrome profile includes elevated TG, low HDL-C, abdominal obesity, and increased diabetes risk.

• Option A: Option A is incorrect; glucocorticoids cause mixed dyslipidemia (TG + LDL-C + reduced HDL-C), not isolated LDL-C elevation; they do not work primarily through PCSK9 upregulation; thiazides do not cause isolated HDL-C reduction via CETP; atypical antipsychotics do not inhibit HMG-CoA reductase.
• Option B: Option B is incorrect; glucocorticoids raise TG significantly — the description of selective LDL-C elevation without TG effect misrepresents their lipid profile; atypical antipsychotics do not work primarily through direct LDL receptor inhibition.
• Option D: Option D is incorrect; glucocorticoids do not selectively raise HDL-C — they cause mixed dyslipidemia with elevated TG and LDL-C; PPARα agonism is the mechanism of fibrates, not glucocorticoids; atypical antipsychotic-induced dyslipidemia primarily involves TG elevation and weight gain, not isolated LDL-C elevation through D2 receptor antagonism.
• Option E: Option E is incorrect; glucocorticoids at 10 mg prednisone daily (a common maintenance anti-inflammatory dose) do produce clinically significant lipid effects with chronic use and are not lipid-neutral at this dose; thiazides do not cause greater than 25% LDL-C elevation and do not require lipid monitoring at every visit as described; atypical antipsychotics primarily cause hypertriglyceridemia and weight gain, not primarily HDL-C reduction.

ANSWER: E

Rationale:

The correct answer is E. Colesevelam (Welchol) is a second-generation bile acid sequestrant with two clinically meaningful advantages over the older resins cholestyramine and colestipol. First, colesevelam has FDA approval for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise, either as monotherapy or in combination with other antidiabetic agents — an indication not shared by the older resins. The glucose-lowering mechanism of colesevelam is not fully established but is hypothesized to involve TGR5 receptor activation on enteroendocrine L-cells in the terminal ileum; TGR5 is a G-protein coupled receptor for bile acids that, when activated, stimulates GLP-1 secretion, enhancing insulin secretion and improving glycemic control. Colesevelam reduces HbA1c by approximately 0.5% in clinical trials — a modest but clinically meaningful reduction that makes it a useful add-on in T2DM patients who also need LDL-C lowering. Second, unlike cholestyramine and colestipol, colesevelam does not cause clinically significant TG elevation in most patients — a property that makes it the preferred resin choice in patients with pre-existing hypertriglyceridemia. The TG-raising effect of older resins is believed to result from increased hepatic VLDL-TG secretion as a consequence of compensatory cholesterol synthesis stimulation; colesevelam's different polymer structure may modify this effect. This patient — with TG already at 220 mg/dL and T2DM — is an ideal candidate for colesevelam over older resins.

• Option A: Option A is incorrect; while colesevelam does achieve equivalent LDL-C lowering at a lower pill burden relative to granular cholestyramine, it does NOT produce the same degree of TG elevation as older resins — this is actually a key distinguishing advantage; the claim of equivalent TG elevation contradicts the correct answer.
• Option B: Option B is incorrect; colesevelam is not absorbed from the GI tract — it is a non-absorbable polymer like all bile acid sequestrants; the claim that it undergoes hepatic metabolism to an active CYP7A1 inhibitor is pharmacologically incorrect; all bile acid sequestrants work exclusively in the intestinal lumen.
• Option C: Option C is incorrect; colesevelam does not activate PPARα in enterocytes — PPARα agonism is the mechanism of fibrates; colesevelam's lack of significant TG elevation is not explained by intestinal PPARα activation.
• Option D: Option D is incorrect; while colesevelam is approved for pediatric use in HeFH patients aged 10–17 and is more convenient than granular preparations, cholestyramine and colestipol are not FDA-restricted to adults only; cholestyramine has been used in pediatric patients; the claim that the FDA restricts older resins exclusively to adults is factually incorrect.

ANSWER: A

Rationale:

The correct answer is A. Statins are contraindicated during pregnancy. All approved statins carry contraindications in pregnancy based on their FDA labeling, reflecting concerns about fetal safety derived from animal teratogenicity studies (which showed skeletal malformations and other adverse developmental outcomes in rodents at pharmacological doses) and from limited human case reports of congenital anomalies in offspring of women who inadvertently took statins during early pregnancy. The mechanistic basis for concern is straightforward: the mevalonate pathway — inhibited by statins — is required for synthesis of cholesterol, which is an essential structural and signaling molecule during fetal development; cholesterol is required for cell membrane integrity, neural tube development, myelination, and as a precursor for steroid hormones and bile acids. Although the fetal liver can synthesize cholesterol endogenously, the concern is that statin-mediated HMG-CoA reductase inhibition could impair this synthesis during critical developmental windows. For a woman with FH planning pregnancy, the recommended approach is to discontinue statins ideally at least one month before attempting conception (or immediately upon recognition of pregnancy if inadvertent conception occurs) and to consider alternative agents that are not systemically absorbed during pregnancy. Bile acid sequestrants — particularly colesevelam — are not absorbed into the systemic circulation and are generally considered acceptable during pregnancy; they will modestly reduce LDL-C during the gestational period. Statins should be resumed after delivery and after breastfeeding is discontinued (statins are also contraindicated in lactation due to concerns about drug secretion into breast milk).

• Option B: Option B is incorrect; statins are not considered safe in any trimester of pregnancy, and the fetus is NOT protected from statin exposure by placental efflux transporters — lipophilic statins in particular cross the placenta to some degree; the claim that P-glycoprotein eliminates all fetal drug exposure regardless of lipophilicity is pharmacologically inaccurate.
• Option C: Option C is incorrect; statins are not FDA Category B — all statins were historically Category X (contraindicated in pregnancy) under the old FDA pregnancy category system, which was replaced in 2015 by the more nuanced Pregnancy and Lactation Labeling Rule (PLLR); the claim that statins are safe in the first trimester and only need to be stopped after 12 weeks inverts the correct guidance, as organogenesis occurs in the first trimester and discontinuation at week 12 does not eliminate the critical risk window.
• Option D: Option D is incorrect; statins should be discontinued preconceptionally and there is no evidence of a clinically harmful "rebound LDL-C" elevation that would justify continuing statins into the first trimester; the recommendation to continue statins through the first trimester and taper in the second trimester is contrary to established prescribing guidance and potentially teratogenic.
• Option E: Option E is incorrect; there is no FDA REMS program permitting statin use during pregnancy in homozygous FH — statins remain contraindicated in pregnancy in all patients with FH regardless of LDL-C severity or genetic subtype; women with HoFH who are pregnant and require lipid-lowering may be managed with LDL apheresis if the situation warrants.